Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

Tenax Therapeutics (TENX)

Tenax Therapeutics Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:TENX
DateTimeSourceHeadlineSymbolCompany
30/04/202412:30GlobeNewswire Inc.Tenax Therapeutics Announces New U.S. Patent Covering the Use of Levosimendan in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)NASDAQ:TENXTenax Therapeutics Inc
09/04/202413:30GlobeNewswire Inc.Tenax Therapeutics to Host KOL Event: “LEVEL Setting: the Scientific Rationale for Levosimendan as a Potential First Treatment for PH-HFpEF, and the Ongoing Phase 3 LEVEL Study”NASDAQ:TENXTenax Therapeutics Inc
28/03/202412:30GlobeNewswire Inc.Tenax Therapeutics Provides Business and Clinical Development Updates with Full Year 2023 Financial ResultsNASDAQ:TENXTenax Therapeutics Inc
12/03/202412:30GlobeNewswire Inc.Tenax Therapeutics to Present at the 36th Annual Roth ConferenceNASDAQ:TENXTenax Therapeutics Inc
29/02/202414:00GlobeNewswire Inc.Tenax Therapeutics Announces Oral Presentation of Levosimendan for the Treatment of PH-HFpEF at THT 2024NASDAQ:TENXTenax Therapeutics Inc
26/02/202421:31Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:TENXTenax Therapeutics Inc
26/02/202421:31Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:TENXTenax Therapeutics Inc
23/02/202421:30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:TENXTenax Therapeutics Inc
21/02/202421:32Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:TENXTenax Therapeutics Inc
21/02/202421:30Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:TENXTenax Therapeutics Inc
20/02/202421:01Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:TENXTenax Therapeutics Inc
20/02/202413:33Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:TENXTenax Therapeutics Inc
20/02/202413:30GlobeNewswire Inc.Tenax Therapeutics Announces Global License Amendment that Significantly Expands Rights to LevosimendanNASDAQ:TENXTenax Therapeutics Inc
16/02/202416:28Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:TENXTenax Therapeutics Inc
16/02/202400:36Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:TENXTenax Therapeutics Inc
14/02/202419:58Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:TENXTenax Therapeutics Inc
13/02/202421:32Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:TENXTenax Therapeutics Inc
12/02/202421:46Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:TENXTenax Therapeutics Inc
09/02/202422:00Edgar (US Regulatory)Form 424B4 - Prospectus [Rule 424(b)(4)]NASDAQ:TENXTenax Therapeutics Inc
08/02/202421:51Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:TENXTenax Therapeutics Inc
08/02/202413:16GlobeNewswire Inc.Tenax Therapeutics Announces Pricing of Approximately $9 Million Public OfferingNASDAQ:TENXTenax Therapeutics Inc
08/02/202405:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:TENXTenax Therapeutics Inc
08/02/202401:01GlobeNewswire Inc.Tenax Therapeutics Enrolls First Patient in Phase 3 LEVEL Study Evaluating TNX-103 (Oral Levosimendan) for the Treatment of Pulmonary Hypertension in Heart Failure with Preserved Ejection Fraction (PH-HFpEF)NASDAQ:TENXTenax Therapeutics Inc
06/02/202414:20Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:TENXTenax Therapeutics Inc
06/02/202413:56Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:TENXTenax Therapeutics Inc
06/02/202413:30GlobeNewswire Inc.Tenax Therapeutics Announces USPTO Grants Notice of Allowance for U.S. Patent Application, Significantly Broadening IP Protection for Use of Levosimendan in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)NASDAQ:TENXTenax Therapeutics Inc
02/02/202422:24Edgar (US Regulatory)Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]NASDAQ:TENXTenax Therapeutics Inc
01/02/202421:20Edgar (US Regulatory)Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]NASDAQ:TENXTenax Therapeutics Inc
22/01/202421:30Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:TENXTenax Therapeutics Inc
19/01/202421:30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:TENXTenax Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:TENX